This review will summarize the CDx approaches and prospective biomarkers associated with PD-1/PD-L1 immunotherapy for malignant melanoma, providing the latest advances in melanoma immunotherapy and new strategies for future development of cancer therapy. Here, CD274 is linked to cancer.